Research Topics
Species | Donald CutlipSummaryAffiliation: Harvard University Country: USA Publications
Research Grants
| Collaborators
|
Detail Information
Publications
Troponin criteria for myocardial infarction after percutaneous coronary interventionVictor Novack
Beth Israel Deaconess Medical Center, 330 Brookline Ave, Boston, MA 02215, USA
Arch Intern Med 172:502-8. 2012....
Drug-eluting stent era: will we improve 5-year outcomes?Donald E Cutlip
Interventional Cardiology Section, Beth Israel Deaconess Medical Center, Harvard Clinical Research Institute, Harvard Medical School, Boston, Massachusetts, USA
Coron Artery Dis 17:681-4. 2006....- Does creatinine kinase-MB elevation after percutaneous coronary intervention predict outcomes in 2005? Cardiac enzyme elevation after successful percutaneous coronary intervention is not an independent predictor of adverse outcomesDonald E Cutlip
Division of Cardiology, Beth Israel Deaconess Medical Center, Harvard Clinical Research Institute, Boston, MA, USA
Circulation 112:916-22; discussion 922. 2005 - Clinical end points in coronary stent trials: a case for standardized definitionsDonald E Cutlip
Harvard Clinical Research Institute, Harvard Medical School, 930 Commonwealth Avenue, Boston, MA 02215, USA
Circulation 115:2344-51. 2007..Although most clinical trials of coronary stents have measured nominally identical safety and effectiveness end points, differences in definitions and timing of assessment have created confusion in interpretation... - Drug-eluting stent era: will we improve 5-year outcomes?Donald E Cutlip
Interventional Cardiology Section, Beth Israel Deaconess Medical Center, Harvard Clinical Research Institute, Harvard Medical School, Boston, Massachusetts 02215, USA
Coron Artery Dis 17:289-92. 2006.... - Effect of tirofiban before primary angioplasty on initial coronary flow and early ST-segment resolution in patients with acute myocardial infarctionDonald E Cutlip
Interventional Cardiology Section, Beth Israel Deaconess Medical Center, Boston, Massacusetts 02215, USA
Am J Cardiol 92:977-80. 2003..20). Patients receiving early tirofiban treatment were more likely to achieve complete (>70%) ST-segment resolution at 90 minutes (69% vs 44%, p = 0.07)... - Autopsy validation study of the academic research consortium stent thrombosis definitionDonald E Cutlip
Cardiovascular Division, Beth Israel Deaconess Medical Center, Boston, Massachusetts 02215, USA
JACC Cardiovasc Interv 4:554-9. 2011..This study sought to validate the sensitivity and specificity of the Academic Research Consortium's (ARC) classification of stent thrombosis... - In-hospital and 1-year outcomes among unselected percutaneous coronary intervention patients treated with either sirolimus- or paclitaxel-eluting stents: results from the EVENT (Evaluation of Drug Eluting Stents and Ischemic Events) registryVictor Novack
Harvard Clinical Research Institute, Boston, Massachusetts, USA
JACC Cardiovasc Interv 2:767-75. 2009..The aim of this study was to compare outcomes among unselected patients undergoing percutaneous coronary intervention (PCI) with either sirolimus-eluting (SES) or paclitaxel-eluting stents (PES)... 
A pilot study examining the severity and outcome of the post-cardiac arrest syndrome: a comparative analysis of two geographically distinct hospitalsMichael W Donnino
Department of Emergency Medicine, Beth Israel Deaconess Medical Center, Boston, MA 02215, USA
Circulation 126:1478-83. 2012..We tested whether hospital-independent factors would account for the difference in outcome between 2 geographically distinct hospitals...- Impact of routine angiographic follow-up on the clinical benefits of paclitaxel-eluting stents: results from the TAXUS-IV trialDuane S Pinto
Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts 02115, USA
J Am Coll Cardiol 48:32-6. 2006.... - Effect of diabetes mellitus on five-year clinical outcomes after single-vessel coronary stenting (a pooled analysis of coronary stent clinical trials)Tobias T Lee
Division of Cardiology, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA
Am J Cardiol 98:718-21. 2006.... - Hospital delays in reperfusion for ST-elevation myocardial infarction: implications when selecting a reperfusion strategyDuane S Pinto
TIMI Study Group and the Cardiovascular Division, Department of Medicine, Beth Israel Deaconess Medical Center, 185 Pilgrim Rd, Boston, MA 02115, USA
Circulation 114:2019-25. 2006..As indicated in the American College of Cardiology/American Heart Association guidelines, both the hospital-based PPCI-related delay (DB-DN time) and patient characteristics should be considered when a reperfusion strategy is selected... - Stent thrombosis in randomized clinical trials of drug-eluting stentsLaura Mauri
Brigham and Women s Hospital, Boston, USA
N Engl J Med 356:1020-9. 2007..Definitions of stent thrombosis that have been used in clinical trials of drug-eluting stents have been restrictive and have not been used in a uniform manner... - Safety and efficacy of sirolimus- and paclitaxel-eluting coronary stentsGregg W Stone
Columbia University Medical Center and the Cardiovascular Research Foundation, New York, NY 10022, USA
N Engl J Med 356:998-1008. 2007..Such studies have been inconclusive because of their insufficient size, the use of historical controls, a limited duration of follow-up, and a lack of access to original source data... - Prevalence and prognostic significance of preprocedural cardiac troponin elevation among patients with stable coronary artery disease undergoing percutaneous coronary intervention: results from the evaluation of drug eluting stents and ischemic events regAllen Jeremias
Division of Cardiovascular Medicine, Stony Brook University Medical Center, Stony Brook, NY, USA
Circulation 118:632-8. 2008.... - Offsetting impact of thrombosis and restenosis on the occurrence of death and myocardial infarction after paclitaxel-eluting and bare metal stent implantationGregg W Stone
Columbia University Medical Center, The Cardiovascular Research Foundation, 111 E 59th St, 11th Floor, New York, NY 10022, USA
Circulation 115:2842-7. 2007..We hypothesized that the prevention of restenosis-related adverse events by drug-eluting stents might offset some or all of the excess risk from ST... - Long-term clinical outcomes with sirolimus-eluting coronary stents: five-year results of the RAVEL trialMarie Claude Morice
Institut Cardiovasculaire Paris Sud, Massy, France
J Am Coll Cardiol 50:1299-304. 2007..This study examined the clinical outcomes at 5 years in RAVEL (A Randomized Comparison of a Sirolimus-Eluting Stent With a Standard Stent for Coronary Revascularization), the first controlled trial of drug-eluting stents... - Comparison of outcomes using sirolimus-eluting stenting in diabetic versus nondiabetic patients with comparison of insulin versus non-insulin therapy in the diabetic patientsRamon Kumar
Department of Medicine, Cardiology Division, Beth Israel Deaconess Medical Center, Boston, MA, USA
Am J Cardiol 100:1187-91. 2007.... - Reduction in sex-based mortality difference with implementation of new cardiology guidelinesVictor Novack
Department of Medicine, Soroka University Medical Center, Beer Sheva, Israel
Am J Med 121:597-603.e1. 2008.... - Saphenous vein graft stenting and major adverse cardiac events: a predictive model derived from a pooled analysis of 3958 patientsAlanna Coolong
Division of Cardiovascular Medicine, Brigham and Women s Hospital, Harvard Medical School, Boston, Mass 02115, USA
Circulation 117:790-7. 2008..Although MACE rates are reduced significantly by the use of embolic protection devices (EPDs), neither the level of baseline risk nor the benefit provided by EPDs has been well characterized... - Differential outcomes after sirolimus-eluting stent implantation: comparing on-label versus off-label patients in the 'real world'Allen Jeremias
Division of Cardiovascular Medicine, Stony Brook University Medical Center, Stony Brook, NY 11794, USA
Coron Artery Dis 19:111-5. 2008..This study examined the performance of SES in a 'real world' setting by comparing the outcomes of trial-eligible versus ineligible patients undergoing percutaneous coronary intervention... - Clinical, procedural, and pharmacologic correlates of acute and subacute stent thrombosis: results of a multicenter case-control study with 145 thrombosis eventsMichael J Rinaldi
Beth Israel Deaconess Medical Center, Boston, MA, USA
Am Heart J 155:654-60. 2008.... - Long-term results of carotid stenting versus endarterectomy in high-risk patientsHitinder S Gurm
University of Michigan School of Medicine, Ann Arbor, USA
N Engl J Med 358:1572-9. 2008..We now report the 3-year results... - Comparison of an everolimus-eluting stent and a paclitaxel-eluting stent in patients with coronary artery disease: a randomized trialGregg W Stone
Columbia University Medical Center, The Cardiovascular Research Foundation, 111 E 59th St, 11th Floor, New York, NY 10022, USA
JAMA 299:1903-13. 2008.... - The Claudication: Exercise Vs. Endoluminal Revascularization (CLEVER) study: rationale and methodsTimothy P Murphy
Rhode Island Hospital Vascular Disease Research Center and Brown Medical School Department of Diagnostic Imaging, Providence, RI 02903, USA
J Vasc Surg 47:1356-63. 2008.... - Two-year outcomes after sirolimus-eluting stent implantation: results from the Sirolimus-Eluting Stent in de Novo Native Coronary Lesions (SIRIUS) trialGiora Weisz
Cardiovascular Research Foundation and Columbia University Medical Center, New York, New York 10032, USA
J Am Coll Cardiol 47:1350-5. 2006.... - Cost-effectiveness of distal embolic protection for patients undergoing percutaneous intervention of saphenous vein bypass grafts: results from the SAFER trialDavid J Cohen
Harvard Clinical Research Institute, Boston, Massachusetts, USA
J Am Coll Cardiol 44:1801-8. 2004..The goal of this research was to determine the incremental cost and cost-effectiveness of embolic protection in patients undergoing percutaneous revascularization (PCI) of diseased saphenous vein bypass grafts (SVGs)... - Protected carotid-artery stenting versus endarterectomy in high-risk patientsJay S Yadav
Cardiovascular Medicine, Cleveland Clinic Foundation, Cleveland, OH 44195, USA
N Engl J Med 351:1493-501. 2004..Stenting with the use of an emboli-protection device is a less invasive revascularization strategy than endarterectomy in carotid-artery disease... - Utility of the Safe-Cross-guided radiofrequency total occlusion crossing system in chronic coronary total occlusions (results from the Guided Radio Frequency Energy Ablation of Total Occlusions Registry Study)Donald S Baim
Brigham and Women s Hospital and Harvard Medical School, Boston, Massachusetts 02120 1613, USA
Am J Cardiol 94:853-8. 2004..Based on these data, the device has been approved in Europe and was recently (January 2004) granted 510K clearance by the Food and Drug Administration... - Differential mortality risk of postprocedural creatine kinase-MB elevation following successful versus unsuccessful stent proceduresAllen Jeremias
Harvard Clinical Research Institute, Division of Cardiology, Beth Israel Deaconess Medical Center, Boston, MA 02215, USA
J Am Coll Cardiol 44:1210-4. 2004..001), but not periprocedural MI. CONCLUSIONS: The association of periprocedural MI with increased mortality during the first year following stent placement was confined to patients with unsuccessful procedures... - Beyond restenosis: five-year clinical outcomes from second-generation coronary stent trialsDonald E Cutlip
Harvard Clinical Research Institute, Beth Israel Deaconess Medical Center, Boston, MA 02215, USA
Circulation 110:1226-30. 2004.... - Effects of stent length and lesion length on coronary restenosisLaura Mauri
Division of Clinical Biometrics, Brigham and Women's Hospital, 1620 Tremont Street, Boston, MA 02120, USA
Am J Cardiol 93:1340-6, A5. 2004..This analysis supports a conservative approach of matching stent length to lesion length to reduce the risk of restenosis with bare metal stents... - Drug-eluting stent task force: final report and recommendations of the working committees on cost-effectiveness/economics, access to care, and medicolegal issuesJohn McB Hodgson
MetroHealth Medical Center, Cleveland, Ohio 44109, USA
Catheter Cardiovasc Interv 62:1-17. 2004..The Task Force trusts that this report will be of value to the diverse constituencies involved with introduction of this important new technology... - Stent thrombosis after successful sirolimus-eluting stent implantationAllen Jeremias
Section of Interventional Cardiology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Mass, USA
Circulation 109:1930-2. 2004..The discontinuation of antiplatelet therapy was strongly associated with the development of ST in this patient population... - Clinical restenosis after coronary stenting: perspectives from multicenter clinical trialsDonald E Cutlip
Harvard Clinical Research Institute, Boston, Massachusetts 02215, USA
J Am Coll Cardiol 40:2082-9. 2002..We sought to evaluate clinical restenosis in a large population of patients who had undergone coronary stent placement... - Effect of gender on in-hospital and one-year outcomes after contemporary coronary artery stentingManish S Chauhan
Lahey Clinic Medical Center, Burlington, Massachsetts 01805, USA
Am J Cardiol 95:101-4. 2005.... - Cutting balloon angioplasty for the prevention of restenosis: results of the Cutting Balloon Global Randomized TrialLaura Mauri
Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, USA
Am J Cardiol 90:1079-83. 2002..CB angioplasty should be reserved for difficult lesions in which controlled dilatation is believed to provide a better acute result compared with balloon angioplasty alone... - Geographical differences in the rates of angiographic restenosis and ischemia-driven target vessel revascularization after percutaneous coronary interventions: results from the Prevention of Restenosis With Tranilast and its Outcomes (PRESTO) TrialMandeep Singh
Division of Internal Medicine and Cardiovascular Diseases, Mayo Clinic and Mayo Foundation, Rochester, Minnesota 55905, USA
J Am Coll Cardiol 47:34-9. 2006..In the absence of a definitive clinical trial to support this view, how should the prudent, cutting-edge cardiologist proceed?.. - Robustness of late lumen loss in discriminating drug-eluting stents across variable observational and randomized trialsLaura Mauri
Brigham and Women s Hospital, Boston, MA 02116, USA
Circulation 112:2833-9. 2005..We hypothesized that mean in-stent late loss might be a more stable estimator of restenosis propensity across such studies... - A pooled analysis of data comparing sirolimus-eluting stents with bare-metal stentsChristian Spaulding
Assistance Publique Hôpitaux de Paris Cochin Hospital, Paris 5 Medical School René Descartes University and INSERM Unité 780 Avenir, Paris
N Engl J Med 356:989-97. 2007..The long-term safety of drug-eluting stents has been questioned recently... - Randomized trial of a distal embolic protection device during percutaneous intervention of saphenous vein aorto-coronary bypass graftsDonald S Baim
Division of Cardiovascular Diseases, Brigham and Women s Hospital, Boston, Mass 02115, USA
Circulation 105:1285-90. 2002..We report the first multicenter randomized trial to evaluate use of a distal embolic protection device during stenting of such lesions... - Comparison of thrombosis and restenosis risk from stent length of sirolimus-eluting stents versus bare metal stentsLaura Mauri
Brigham and Women's Hospital, Boston, Massachusetts 02115, USA
Am J Cardiol 95:1140-5. 2005..Longer stent-to-lesion length strategies should be used only when a shorter stent is likely to result in incomplete lesion coverage and edge dissection, a strong determinant of stent thrombosis... - Relationship of late loss in lumen diameter to coronary restenosis in sirolimus-eluting stentsLaura Mauri
Brigham and Women's Hospital, Boston, Mass 02116, USA
Circulation 111:321-7. 2005..Late loss is monotonically correlated with the probability of restenosis and yields a more efficient estimate of the restenosis process in the era of lower binary restenosis rates... - Rheolytic thrombectomy and platelet glycoprotein IIb/IIIa blockade for stent thrombosisStephane Rinfret
Cardiovascular Division, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts 02215, USA
Catheter Cardiovasc Interv 57:24-30. 2002..A combined approach of rheolytic thrombectomy with adjunctive GP IIb/IIIa blockade was highly effective in resolving stent thrombosis and was associated with favorable acute and long-term outcomes... - Determinants of 30-day adverse events following saphenous vein graft intervention with and without a distal occlusion embolic protection deviceGregory R Giugliano
Division of Cardiology, Brigham and Women's Hospital, One Brigham Circle, Boston, MA 02115, USA
Am J Cardiol 95:173-7. 2005.... - Incidence and predictors of late total occlusion following coronary stentingPinak B Shah
Cardiovascular Division, St Elizabeth s Medical Center, Boston, Massachusetts 02135, USA
Catheter Cardiovasc Interv 60:344-51. 2003..004), longer stent length (P < 0.001), and smaller preprocedure MLD (P = 0.012) were independent predictors of total occlusion following coronary stenting... - Comparison of rotational atherectomy with conventional balloon angioplasty in the prevention of restenosis of small coronary arteries: results of the Dilatation vs Ablation Revascularization Trial Targeting Restenosis (DART)Laura Mauri
Swedish Hospital, Seattle, Wash, USA
Am Heart J 145:847-54. 2003..Because the acute gain and loss index ratios of the 2 treatments were similar, there was no evident beneficial antirestenosis mechanism seen for rotational atherectomy... - Four-year clinical follow-up after implantation of the endeavor zotarolimus-eluting stent: ENDEAVOR I, the first-in-human studyIan T Meredith
Monash Medical Centre and Monash University, Melbourne, Australia
Am J Cardiol 100:56M-61M. 2007..The treatment of patients with symptomatic CAD due to de novo lesions in native coronary arteries with the Endeavor ZES has sustained clinical benefits to 4 years, with very low rates of MACE and TLR... - Risk of target lesion revascularization after coronary stenting in patients with and without chronic kidney diseaseDavid Charytan
Department of Medicine, Brigham and Women s Hospital, Renal Division, Clinical Biometrics, 1 Brigham Circle, 3rd Floor, Boston, MA 02115, USA
Nephrol Dial Transplant 22:2578-85. 2007..Whether mild to moderate chronic kidney disease (CKD) is associated with a similarly increased need for short or long-term target lesion revascularization (TLR) following coronary stenting is uncertain... - Drug eluting stents for ST-elevation myocardial infarction: risk and benefitJason Ryan
Beth Israel Deaconess Medical Center and Harvard Medical School, 1 Deaconess Road, Boston, MA 02215, USA
J Thromb Thrombolysis 24:293-9. 2007..This review with discuss the theoretical risks and benefits of DES for STEMI, the available data regarding their use, and the areas where future studies are needed... - Obesity and clinical restenosis after coronary stent placementJamal S Rana
Cardiovascular Division, Department of Medicine, Beth Israel Deaconess Medical Center, Boston, MA, USA
Am Heart J 150:821-6. 2005..The significant association of severe obesity in nondiabetic and normotensive patients suggests that other obesity-associated mechanisms such as insulin resistance and inflammation should be further explored... - Relationship of chronic kidney disease to cardiovascular death and myocardial infarction following coronary stentingDavid M Charytan
Department of Medicine, Brigham and Women s Hospital, Boston, Massachusetts 02120, USA
J Nephrol 19:764-70. 2006.... - Gender-specific outcomes after sirolimus-eluting stent implantationEmilia Solinas
Columbia University Medical Center and the Cardiovascular Research Foundation, New York, New York, USA
J Am Coll Cardiol 50:2111-6. 2007..We examined the impact of gender on outcomes of patients undergoing percutaneous coronary intervention using sirolimus-eluting stents (SES)...
Research Grants
- Claudication Exercise vs Endoluminal RevascularizationDonald Cutlip; Fiscal Year: 2007..Recruitment will be done over 28 months and patients will be followed for 18 months; the total study duration will be 5 years. ..